In my practice, I’ve used all the NOAC (novel anticoagulant) therapies available for stroke prevention in my nonvalvular atrial fibrillation patients. I have used dabigatran in my nonvalvular atrial ...

A new version of the EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation is published online today in European Heart Journal ...

Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting ...

Warfarin, the longtime standard treatment for atrial fibrillation, is facing competition from new options in the anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. A new ...

Patients on oral anticoagulants who experience a bleeding event may be able to discontinue therapy if certain circumstances apply, according to updated guidance from the American College of Cardiology ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin. Novel oral anticoagulants (NOACs) lead to a one-fifth reduction in the risk ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — As the number of available novel oral anticoagulants expands, physicians must consider how best to ...

Anticoagulants are medications that help stop your blood from thickening or “clotting.” Your body does need to be able to clot to help seal wounds inside and outside your body. But unnecessary clots ...

There are currently 4 non-vitamin K antagonist anticoagulants available. These NOAC (novel anticoagulant) therapies include dabigatran, rivaroxaban, apixaban, and edoxaban. First, it’s important to ...